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With the aim to dissect the effect of adult height on head and neck cancer (HNC), we use the Mendelian 
randomization (MR) approach to test the association between genetic instruments for height and 
the risk of HNC. 599 single nucleotide polymorphisms (SNPs) were identified as genetic instruments 
for height, accounting for 16% of the phenotypic variation. Genetic data concerning HNC cases 
and controls were obtained from a genome-wide association study. Summary statistics for genetic 
association were used in complementary MR approaches: the weighted genetic risk score (GRS) and the 
inverse-variance weighted (IVW). MR-Egger regression was used for sensitivity analysis and pleiotropy 
evaluation. From the GRS analysis, one standard deviation (SD) higher height (6.9 cm; due to genetic 
predisposition across 599 SNPs) raised the risk for HNC (Odds ratio (OR), 1.14; 95% Confidence Interval 
(95%CI), 0.99–1.32). The association analyses with potential confounders revealed that the GRS was 
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associated with tobacco smoking (OR = 0.80, 95% CI (0.69–0.93)). MR-Egger regression did not provide 
evidence of overall directional pleiotropy. Our study indicates that height is potentially associated 
with HNC risk. However, the reported risk could be underestimated since, at the genetic level, height 
emerged to be inversely associated with smoking.
Head and neck cancer (HNC) is the seventh most common cancer worldwide, with more than a half million new 
cases in 20121.
This includes carcinomas of the upper aerodigestive tract (UADT: oral cavity, nasopharynx, oropharynx, 
hypopharynx, and larynx), the paranasal sinuses, and the salivary glands, being squamous cell carcinoma the 
most common histopathological type2.
Tobacco smoking and alcohol consumption are the main environmental risk factors for HNC3–5, although 
other factors, including infection from human papillomavirus (HPV), low physical activity, poor diet, and low 
socioeconomic status, affect the risk6–10. Adult height has also been observed as a risk factor for HNC11, among 
other cancer outcomes12–21. In the prospective NIH-AARP cohort study, with 218,854 participants aged between 
50 and 71, it was observed a 34% risk increase for HNC among individuals in the fourth quartile of height11. 
However, inverse associations have also been reported22. These inconsistencies could be due to different study 
designs and potential residual confounding.
To circumvent these limitations of observational studies, Mendelian randomization (MR) is a technique 
aimed at validation of causal effects using genetics23. MR analysis uses an instrumental variable (IV) (e.g., genetic 
variant that proxies for directly measured exposures) to make causal inferences about the relationship between a 
risk factor and an outcome. The advantage of using germ-line genetic instruments lays in the fact that they have 
less probability to be associated with environmental confounders or reverse causation. Additionally, the use of 
multiple genetic variants as instruments can improve the precision of IV estimates and the statistical power of the 
study24,25. Two strategies exist to combine information on multiple uncorrelated IVs into a single causal estimate: 
using individual-level genetic data or summary statistics for genetic association. In the former, a polygenetic risk 
score for the exposure can be tested for risk on case-control samples; in the latter, individual IV casual estimates 
are combined in an inverse-variance weighted (IVW) fixed-effect meta-analysis26. However, an enlarged set of 
genetic variants is more likely to contain invalid IVs, due to the inclusion of pleiotropic variants which can lead 
to biased causal effect estimates. In order to overcome this potential issue, MR approaches for data with multiple 
potentially invalid instruments have been developed. The presence of overall directional pleiotropy on the esti-
mated casual effect can be assessed using an adaption of the Egger regression (MR-Egger)27.
Adult height is indeed determined by a combination of genetic factors and environmental exposures, both in 
utero and during childhood and adolescence. In Caucasian population, heritability of adult height is estimated to 
account for ~80%, while the remaining ~20% is due to environmental factors28,29. Recent genome-wide associa-
tion studies (GWAS) have been identified hundreds of genomic loci linked to human height30,31, which account 
for approximately 16% of phenotypic variation.
The aim of this MR study is to dissect the causal effect of height on HNC cancer in subjects of European ances-
try using height-related genetic variants as proxies for height on HNC cancer samples.
Methods
Selection of instrumental variables and study sample. A total of 697 single nucleotide polymor-
phisms (SNPs) were identified as genome-wide associated (p-value < 5 × 10−8), from a recently published GWAS 
on adult height including 253,288 individuals of European ancestry31.
Individual-level genetic data concerning HNC cases and controls were obtained from a recent GWAS on 
UADT cancers. The GWAS was carried out in 2,091 UADT cancer cases and 3,513 controls from two large 
European hospital-based multi-center studies. These studies were the International Agency for Research on 
Cancer (IARC) central Europe (CE) study conducted from 2000 to 2002, in 6 centers from 5 countries; and 
Alcohol-Related Cancers and Genetic susceptibility in Europe (ARCAGE) study conducted by IARC from 2002 
to 2005, in 12 centers from 9 European countries32. Cases and controls were matched by age and center with 
a control/case ratio of 1 for ARGACE and 2–3 for CE study. We conducted quality control steps on these data 
using PLINK software33. Genetic variants and individuals with genotype call rate of less than 95% were excluded 
for the analyses. We also conducted further exclusions where the genotype distribution clearly deviated from 
that expected by Hardy-Weinberg Equilibrium (HWE) among controls (genome-wide P threshold of 1 × 10−7). 
Genetic principal components (PCs) for population stratification were estimated using 12,898 genetic variants 
in low linkage disequilibrium (LD) (R2 < 0.01). Genotype imputation has been performed using MACH 1.034,35, 
and the 1000 Genomes Project ALL panel (Phase I integrated Release 3) as haplotype reference panel. Imputed 
SNPs were restricted on the basis of imputed accuracy, and only SNPs with higher imputation quality (R2) than 
0.7 were selected for our analyses.
Available phenotypic data for these samples comprised: age, sex (female vs male), country of origin, height, 
tobacco smoking (coded as never vs ever smokers), alcohol consumption (coded as never vs ever drinkers) and 
HNC status.
Observed risk and power assessment of Mendelian randomization analyses. Initially, we eval-
uated which was the observed risk for the phenotypic height-HNC status association. HNC status was regressed 
on standardized height controlling for age, sex, country of origin, tobacco smoking and alcohol consumption sta-
tus (HNC status ~ height + age + sex + country of origin + smoking status + alcohol consumption status). Then, 
to evaluate the power to validate the observed risk estimates using the MR approach, power calculations were 
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performed based on the number of total cases and controls and the explained proportion of phenotype variance 
explained by the set of genetic instruments (16%29)36.
Mendelian randomization analyses. Complementary MR approaches were performed in this study. 
First, a weighted genetic risk score (GRS) of previously selected SNPs was used as IV for adult height. For each 
genotype, participants received a score of 0, 1, or 2, when carrying 0, 1, or 2 height-increasing alleles, respec-
tively. Each allele dosage was weighted by the per-allele change in 1 standard deviation (SD) of height (6.9 cm) 
reported in the original published study31 (GRS = ΣβGPi*IVidosage; where i ranges from 1 to total number of 
IVs). The derived weighted GRS was tested under an additive model as IV to assess the effect of height on HNC. 
Firstly, we predicted height from the weighted GRS using a linear model and adjusting by age, sex and 15 PCs 
(Height ~ GRS + age + sex + 15 PCs). Similarly, we assessed the relationship between the weighted GRS and 
each measured potential confounding factor, namely age, sex, country of origin, tobacco smoking and alcohol 
consumption status (e.g., smoking status ~ GRS + age + sex + 15 PCs). Finally, we regressed the disease status on 
the weighted GRS and adjusted for covariates, including age, sex, country of origin, tobacco smoking, alcohol 
consumption, and 15 PCs (HNC status ~ GRS + age + sex + country of origin + smoking status + alcohol con-
sumption status + 15 PCs). The obtained coefficient was then evaluated as the estimated effect of adult height on 
HNC. Additionally, we also examined the height-HNC association separately for men and women, and among 
HNC studies (CE and ARCAGE).
The other MR approaches were performed using the summary statistics for genetic association of selected 
SNPs on height (βGPi; from height GWAS) and on HNC status (βGDi: from HNC status ~IVi + age + sex + country 
of origin + smoking status + alcohol consumption status + 15 PCs). A causal effect estimate of height on HNC 
was obtained through IVW fixed-effect meta-analysis of SNP Wald ratios (βGDi/βGPi), whose weights are described 
as βGPi2/SeβGD (Se: standard error), constraining the regression intercept to zero36. If all genetic variants satisfy the 
IV assumptions, then the IVW estimate is a consistent estimate of the causal effect, as it is a weighted mean of the 
individual ratio estimates. As a sensitivity analysis of the effect of potential directional pleiotropy on the estimated 
causal effects, an adaption of Egger regression (MR-Egger) was performed on the Wald ratios without constrain-
ing the intercept of the regression27. The estimated value of the intercept in the Egger regression is interpreted as 
an estimate of the average pleiotropic effect across the genetic variants. An intercept term that differs from zero is 
indicative of overall directional pleiotropy. Similarly, these MR approaches were applied within subgroups of sex 
and studies. Statistical analysis was performed using Stata software (StataCorp. 2013. Stata Statistical Software: 
Release 13. College Station, TX: StataCorp LP).
Results
A total of 2,082 HNC cases (65.4% from ARCAGE study and 82.8% males) and 3,477 controls (37.6% from 
ARCAGE study and 73.6% males) passed quality control steps. The mean adult height (in cm) among female and 
male controls was 161.8 (SD, 6.7) and 173.7 (SD, 7.0), respectively, whereas among HNC cases, the mean height 
among females was 161.6 (SD, 6.3) and among males was 172.3 (SD, 7.0) (Table S1 for the multi-center description).
Among both females and males, the proportion of ever smokers was about 1.5-fold higher in HNC cases than 
in controls (65.4% vs. 38.2% and 95.3% vs. 74.8%, respectively) (Table 1). Ever smokers were also more frequent 
in ARCAGE study (78%) compared with Central Europe study (71%). The proportion of ever drinkers among 
HNC cases was of 77.9% and 97.7%, respectively in females and in males (Table 1). Ever drinkers did not differ 
among studies (91% in ARCAGE and 92% in Central Europe).
The observed risk of HNC for each SD increase in phenotypic height was of 1.24 (95% CI, 1.15-1.34) (Fig. 1). 
The analysis stratified by study showed heterogeneity on the risk estimates, each SD increase in height provided 
an OR = 1.16 (1.05–1.27) for ARCAGE and an OR = 1.39 (1.23–1.57) for central Europe (Fig. 1). Similarly, dif-
ferent risk estimates were observed in the analysis stratified by gender, each SD increase in height provided an 
OR = 1.28 (1.18–1.39) for men and an OR = 1.07 (0.89–1.28) for women (Fig. 1).
Females (n = 1275) Males (n = 4284)
Controls mean 
(sd) or n (%)
HNC cases mean 
(sd) or n (%) P value
Controls mean 
(sd) or n (%)
HNC cases mean 
(sd) or n (%) P value
Total 917 (100%) 358 (100%) 2560 (100%) 1724 (100%)
Age (years) 59.8 (11.7) 60.8 (11.7) 0.18 59.4 (10.3) 58.7 (9.7) 0.03
Height (cm) 161.8 (6.7) 161.6 (6.3) 173.7 (7.0) 172.3 (7.0)
Smoking status <0.001 <0.001
Never smokers 567 (61.8%) 124 (34.6%) 641 (25.1%) 81 (4.7%)
Ever smokers 350 (38.2%) 234 (65.4%) 1916 (74.8%) 1643 (95.3%)
Missing 0 (0.0%) 0 (0.0%) 3 (0.1%) 0 (0.0%)
Drinking status <0.001 <0.001
Never drinkers 222 (24.2%) 78 (21.8%) 119 (4.6%) 38 (2.2%)
Ever drinkers 694 (75.7%) 279 (77.9%) 2441 (95.4%) 1685 (97.7%)
Missing 1 (0.1%) 1 (0.3%) 0 (0.0%) 1 (0.1%)
Table 1. Population characteristics of the studied sample, stratified by gender. Notes: HNC: head and neck 
cancer; SD: standard deviation.
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Power estimates of MR analyses to validate observed risk estimates can be observed in Figure S1. The power 
to validate a risk increase of 1.24 was 81.5%.
Among those SNPs identified as instruments for height, a total number of 599 SNPs resulted with high impu-
tation quality and were genetically independent (linkage disequilibrium R2 < 0.01), as listed in Table S2, and 
were thus used to derive the weighted GRS. None of the 599 SNPs was associated with HNC risk (P < 1 × 10−5, 
Table S2).
The weighted GRS was normally distributed in both HNC cases and controls. The GRS was strongly asso-
ciated with height (one unit of GRS equaled to 5.05 cm of height, 95% CI (4.65–5.46)). The analysis of the rela-
tion between the GRS and potential measured confounders revealed that the GRS was not associated with age 
(P-value = 0.14), country of origin (P-value = 0.85), and alcohol consumption (P-value = 0.14). However, the GRS 
was associated with sex (OR = 1.21, 95% CI (1.04–1.41)), and tobacco smoking (OR = 0.80, 95% CI (0.69–0.93)).
Regarding HNC status, each SD increase in height (6.9 cm in Wood et al.29) provided an OR = 1.14 (95% 
CI, 0.99–1.32). In the analysis stratified by study, this risk increase was observed for the Central Europe study 
(OR = 1.27 (1.02–1.57)), but not for ARCAGE (OR = 1.05 (0.86–1.27)) (Fig. 1). Conversely, the risk increase 
among sex was similar (OR = 1.13 (0.96–1.32) for men and OR = 1.16 (0.84–1.62) for women) (Fig. 1).
The IVW approach provided similar risk estimates for the overall sample (OR = 1.11 (0.96–1.28)) and for the 
stratified analyses than GRS results (Fig. 1).
Finally, since there was no evidence that the MR-Egger regression intercept was different from zero (data not 
shown), for both the overall and the stratified analyses, no overall directional pleiotropic effect was detected bias-
ing our previous causal effect estimates. MR-Egger causal estimates can be observed in Fig. 1.
As further sensitivity analyses, we estimated the MR overall effects of height on HNC risk using a set of 448 
SNPs with a higher imputation quality (R2 > 0.9). The results from GRS analysis did not differ from previous 
ones (OR pooled sample = 1.16 (0.99–1.37); OR Central Europe study = 1.32 (1.03–1.70); OR ARCAGE = 1.03 
(0.83–1.29); OR men = 1.06 (0.72–1.55); and OR women = 1.16 (0.97–1.39)).
Discussion
The aim of this study was to validate the observed association between height and HNC using genetic proxies for 
height and providing causal effect estimate free from confounding effects.
Our study indicates that adult height is potentially associated with HNC risk. However, height emerged 
to be inversely associated with smoking. Therefore, if shorter individuals are more likely to smoke, this could 
be masking the height-HNC relationship, and the reported effect of height on HNC could be underestimated. 
Additionally, using complementary MR approaches, the MR risk estimates were in the same risk direction of the 
conventional phenotypic analysis, but providing lower risk estimates. This could suggest that the observed risk 
effect of phenotypic height on HNC could be considered a real causal estimate for HNC (since our genetic effects 
could be underestimated), and/or that the real causal effect is moderate and there exist other factors correlated 
Figure 1. Odds ratios and 95% confidence intervals (95% CI) for the association between the weighted genetic 
risk score (GRS), the inverse-variance weighted (IVW) estimate, and the Egger Method (MR-Egger) and the 
risk of head and neck (HNC).
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with phenotypic height that also contribute to HNC risk. The slightly observed study heterogeneity could be par-
tially due to different proportion of ever smokers, being the proportion of smokers higher in the ARCAGE and, 
thus, attenuating the HNC risk estimate. Additionally, the gender heterogeneity that was found in this study has 
already been discussed by Walter et al., that reported height as an important explanatory factor for the excess risk 
for men for many shared-site cancers37.
A direct biological explanation for the recently observed associations between height and HNC can be hypoth-
esized. The loci found in GWAS are enriched for genes encoding for cytoskeleton and extracellular matrix pro-
teins, proteasis, cell cycle controllers, metabolic enzymes, chromatic molecules, transcription factors and other 
signaling proteins mainly controlling skeletal growth, body metabolism, cell growth and division regulation, 
cellular differentiation, senescence and programmed death38. Human stature and tumor development appear to 
share fundamental control mechanisms. Such activities play crucial roles in tumor growth and malignant progres-
sion, in support of findings that relate height with cancer risk.
Additionally, the controversy at the basis of the causal relationship between height and HNC risk could be 
explained through independent effects of environmental risk factors towards both height and HNC risk, or indi-
rect effects of height on HNC risk mediated by behavior risk factors. Examples of the former would be long term 
effects of in utero nutrition and exposure to hormones, psychological well-being during childhood, the timing 
of puberty, family social class, and crowded housing which increase the risk of shorter stature in adulthood15,39. 
Examples of the latter would be height determining several aspects of living conditions, with shorter height lead-
ing to lower levels of education, lower job status and less income, which was revealed by a MR study, particularly 
in men40. Thus, it appears that adult height could directly increase the risk of HNC, but generate, at the same time, 
controversial results for HNC risk, through direct or indirect determination of human behavior (our findings 
that taller stature negatively associates with tobacco smoking, and the heterogeneity observed among studies).
Some limitations can be derived from our study. First, MR assumptions are not completely satisfied. Those 
include that the genetic IV must be associated with the risk factor of interest, must be independent of potential 
confounders, and can only affect the outcome through the risk factor. The first assumption is satisfied since IVs 
were identified from the largest GWAS on height. However, the other two assumptions are not feasible to validate. 
In our study, we tested the association of our GRS with some potential HNC risk factors, and the GRS was found 
to be negatively associated with tobacco smoking. This result implies potential bias in our estimate of the effect of 
height on HNC risk, potentially underestimating the true causal effect. Second, the use of a large number of SNPs 
as instruments raises the chance to introduce bias due to pleiotropy in our MR results. However, the use of com-
plementary MR approaches with different sensitivity to these pleiotropic effects providing similar risk estimates 
gave robustness to our results. Finally, since we were not able to stratify our analysis by HNC subtypes, we cannot 
provide a measure of the association between height and the specific HNC subtypes.
In conclusion, our MR study reported an inverse association between adult height and tobacco smoking and 
a potential association between adult height and HNC. Given the quite large disparities in population average 
height, even within Europe, and the quite different trends in human adult height40,41, our MR study could have 
potential implications for public health interventions.
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